A pharmacological primer of biased agonism

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 92-98

  Andresen, Bradley T ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b Harry S Truman Veterans Affairs Medical Center   (United States)

Author keywords

Arrestin; Beta adrenergic receptors; Biased agonism; G protein coupled receptor kinases (GRKs); G protein coupled receptors (GPCRs); Pharmacology

Indexed keywords

ALPRENOLOL; ANGIOTENSIN 1 RECEPTOR; CARVEDILOL; CHEMOKINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; PARATHYROID HORMONE RECEPTOR;

ARTICLE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 79956283986     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011795564179     Document Type: Article

References (59)

1. Wisler, J.W.; DeWire, S.M.; Whalen, E.J.; Violin, J.D.; Drake, M.T.; Ahn, S.; Shenoy, S.K. and Lefkowitz, R.J. (2007) A unique mechanism of beta-blocker action: carvedilol stimulates betaarrestin signaling. Proc. Natl. Acad. Sci. USA, 104, 16657-16662.
2. Kenakin, T.P. (2001) Quantitation in receptor pharmacology. Receptors. Channels, 7, 371-385.
3. Kenakin, T. (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J., 15, 598-611.
4. Kenakin, T. (2004) Principles: receptor theory in pharmacology. Trends Pharmacol. Sci., 25, 186-192.
5. Kenakin, T. (2009) Quantifying Biological Activity in Chemical Terms: A Pharmacology Primer to Describe Drug Effect. ACS Chem. Biol., 4, 249-260.
6. Polc, P.; Bonetti, E.P.; Schaffner, R. and Haefely, W. (1982) A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone. Naunyn Schmiedebergs Arch. Pharmacol., 321, 260-264.
7. Jordan, V.C.; Phelps, E. and Lindgren, J.U. (1987) Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat., 10, 31-35.
8. Shang, Y. and Brown, M. (2002) Molecular determinants for the tissue specificity of SERMs. Science, 295, 2465-2468.
9. Wise, A.; Gearing, K. and Rees, S. (2002) Target validation of Gprotein coupled receptors. Drug Discov. Today, 7, 235-246.
10. Benovic, J.L.; Pike, L.J.; Cerione, R.A.; Staniszewski, C.; Yoshimasa, T.; Codina, J.; Caron, M.G. and Lefkowitz, R.J. (1985) Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J. Biol. Chem., 260, 7094- 7101.
11. Findlay, D.M.; Michelangeli, V.P. and Robinson, P.J. (1989) Protein kinase-C-induced down-regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN cells. Endocrinology, 125, 2656-2663.
12. Lee, N.H. and Fraser, C.M. (1993) Cross-talk between m1 muscarinic acetylcholine and beta 2-adrenergic receptors. cAMP and the third intracellular loop of m1 muscarinic receptors confer heterologous regulation. J. Biol. Chem., 268, 7949-7957.
13. Benovic, J.L.; Strasser, R.H.; Caron, M.G. and Lefkowitz, R.J. (1986) Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc. Natl. Acad. Sci. USA, 83, 2797-2801.
14. Benovic, J.L.; Mayor, F.Jr.; Somers, R.L.; Caron, M.G. and Lefkowitz, R.J. (1986) Light-dependent phosphorylation of rhodopsin by beta-adrenergic receptor kinase. Nature, 321, 869-872.
15. Sibley, D.R.; Strasser, R.H.; Benovic, J.L.; Daniel, K. and Lefkowitz, R.J. (1986) Phosphorylation/dephosphorylation of the betaadrenergic receptor regulates its functional coupling to adenylate cyclase and subcellular distribution. Proc. Natl. Acad. Sci. USA, 83, 9408-9412.
16. Ferguson, S.S.; Downey, W.E.III; Colapietro, A.M.; Barak, L.S.; Menard, L. and Caron, M.G. (1996) Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science, 271, 363-366.
17. Gurevich, V.V.; Dion, S.B.; Onorato, J.J.; Ptasienski, J.; Kim, C.M.; Sterne-Marr, R.; Hosey, M.M. and Benovic, J.L. (1995) Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2- adrenergic, and m2 muscarinic cholinergic receptors. J. Biol. Chem., 270, 720-731.
18. Goodman, O.B.Jr.; Krupnick, J.G.; Santini, F.; Gurevich, V.V.; Penn, R.B.; Gagnon, A.W.; Keen, J.H. and Benovic, J.L. (1996) Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2- adrenergic receptor. Nature, 383, 447-450.
19. Luttrell, L.M.; Ferguson, S.S.; Daaka, Y.; Miller, W.E.; Maudsley, S.; Della, R.G.J.; Lin, F.; Kawakatsu, H.; Owada, K.; Luttrell, D.K.; Caron, M.G. and Lefkowitz, R.J. (1999) Beta-arrestindependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science, 283, 655-661.
20. Ye, S.; Zaitseva, E.; Caltabiano, G.; Schertler, G.F.; Sakmar, T.P.; Deupi, X. and Vogel, R. (2010) Tracking G-protein-coupled receptor activation using genetically encoded infrared probes. Nature, 464, 1386-1389.
21. Sterne-Marr, R.; Leahey, P.A.; Bresee, J.E.; Dickson, H.M.; Ho, W.; Ragusa, M.J.; Donnelly, R.M.; Amie, S.M.; Krywy, J.A.; Brookins-Danz, E.D.; Orakwue, S.C.; Carr, M.J.; Yoshino-Koh, K.; Li, Q. and Tesmer, J.J. (2009) GRK2 activation by receptors: role of the kinase large lobe and carboxyl-terminal tail. Biochemistry, 48, 4285-4293.
22. Boguth, C.A.; Singh, P.; Huang, C.C. and Tesmer, J.J. (2010) Molecular basis for activation of G protein-coupled receptor kinases. EMBO J., 29, 3249-3259.
23. Shukla, A.K.; Violin, J.D.; Whalen, E.J.; Gesty-Palmer, D.; Shenoy, S.K. and Lefkowitz, R.J. (2008) Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. USA, 105, 9988-9993.
24. Noma, T.; Lemaire, A.; Naga Prasad, S.V.; Barki-Harrington, L.; Tilley, D.G.; Chen, J.; Le, C.P.; Violin, J.D.; Wei, H.; Lefkowitz, R.J. and Rockman, H.A. (2007) Beta-arrestin-mediated beta1- adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest., 117, 2445-2458.
25. Galandrin, S.; Oligny-Longpre, G.; Bonin, H.; Ogawa, K.; Gales, C. and Bouvier, M. (2008) Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol. Pharmacol., 74, 162-172.
26. Kim, I.M.; Tilley, D.G.; Chen, J.; Salazar, N.C.; Whalen, E.J.; Violin, J.D. and Rockman, H.A. (2008) {beta}-Blockers alprenolol and carvedilol stimulate {beta}-arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. USA, 105, 14555-14560.
27. Johnstone, M. (1968) Alprenolol during halothane anaesthesia in surgical patients. Acta Anaesthesiol. Scand., 12, 183-190.
28. U.S.Food and Drug Administration. FDA Approves First Generic Versions of Coreg. FDA News Release. 2007.
29. U.S.Food and Drug Administration (2010) Approved Drug Products with Therapeutic Equivalence Evaluations, 30th edn.
30. Drug Topics staff. Pharmacy Facts & Figures. Drug Topics. 2010.
31. Vanderhoff, B.T.; Ruppel, H.M. and Amsterdam, P.B. (1998) Carvedilol: the new role of beta blockers in congestive heart failure. Am. Fam. Physician, 58, 1627-1622.
32. Nicholson, R.I.; Gee, J.M. and Harper, M.E. (2001) EGFR and cancer prognosis. Eur. J. Cancer, 37 Suppl 4, S9-15.
33. Ciardiello, F. and Tortora, G. (2008) EGFR antagonists in cancer treatment. N. Engl. J. Med., 358, 1160-1174.
34. Mendelsohn, J. and Baselga, J. (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 21, 2787-2799.
35. Sheehy, A.M.; Phung, Y.T.; Riemer, R.K. and Black, S.M. (1997) Growth factor induction of nitric oxide synthase in rat pheochromocytoma cells. Brain Res. Mol. Brain Res., 52, 71-77.
36. Mehta, V.B.; Zhou, Y.; Radulescu, A. and Besner, G.E. (2008) HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors, 26, 301-315.
37. Zhou, Y.; Brigstock, D. and Besner, G.E. (2009) Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles. Microvasc. Res., 78, 78-85.
38. Namiki, A. and Akatsuka, N. (1990) Vascular smooth muscle relaxation induced by epidermal growth factor is endotheliumdependent. Eur. J. Pharmacol., 180, 247-254.
39. Kurosaki, K.; Ikeda, U.; Maeda, Y. and Shimada, K. (2000) Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J. Mol. Cell Cardiol., 32, 333-339.
40. Afonso, R.A.; Patarrao, R.S.; Macedo, M.P. and Carmo, M.M. (2006) Carvedilol action is dependent on endogenous production of nitric oxide. Am. J. Hypertens., 19, 419-425.
41. Abrams, J. (1996) Beneficial actions of nitrates in cardiovascular disease. Am. J. Cardiol., 77, 31C-37C.
42. Grossman, E.; Messerli, F.H. and Goldbourt, U. (2001) Antihypertensive therapy and the risk of malignancies. Eur. Heart J., 22, 1343-1352.
43. Fryzek, J.P.; Poulsen, A.H.; Lipworth, L.; Pedersen, L.; Norgaard, M.; McLaughlin, J.K. and Friis, S. (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res. Treat., 97, 231-236.
44. Perron, L.; Bairati, I.; Harel, F. and Meyer, F. (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control, 15, 535-541.
45. Tilley, D.G.; Kim, I.M.; Patel, P.A.; Violin, J.D. and Rockman, H.A. (2009) beta-Arrestin mediates beta1-adrenergic receptorepidermal growth factor receptor interaction and downstream signaling. J. Biol. Chem., 284, 20375-20386.
46. McCole, D.F.; Truong, A.; Bunz, M. and Barrett, K.E. (2007) Consequences of direct versus indirect activation of epidermal growth factor receptor in intestinal epithelial cells are dictated by proteintyrosine phosphatase 1B. J. Biol. Chem., 282, 13303-13315.
47. Stanojkovic, T.P.; Zizak, Z.; Mihailovic-Stanojevic, N.; Petrovic, T. and Juranic, Z. (2005) Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J. Exp. Clin. Cancer Res., 24, 387-395.
48. Yuan, A.; Li, Z.; Li, X.; Yi, S.; Wang, S.; Cai, Y. and Cao, H. (2010) The mitogenic effectors of isoproterenol in human hepatocellular carcinoma cells. Oncol. Rep., 23, 151-157.
49. Cakir, Y.; Plummer, H.K.III; Tithof, P.K. and Schuller, H.M. (2002) Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int. J. Oncol., 21, 153- 157.
50. Zhang, D.; Ma, Q.Y.; Hu, H.T. and Zhang, M. (2010) beta2- adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol. Ther., 10, 19-29.
51. Sood, A.K.; Bhatty, R.; Kamat, A.A.; Landen, C.N.; Han, L.; Thaker, P.H.; Li, Y.; Gershenson, D.M.; Lutgendorf, S. and Cole, S.W. (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res., 12, 369-375.
52. Guo, K.; Ma, Q.; Wang, L.; Hu, H.; Li, J.; Zhang, D. and Zhang, M. (2009) Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol. Rep., 22, 825-830.
53. Yang, E.V.; Sood, A.K.; Chen, M.; Li, Y.; Eubank, T.D.; Marsh, C.B.; Jewell, S.; Flavahan, N.A.; Morrison, C.; Yeh, P.E.; Lemeshow, S. and Glaser, R. (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res., 66, 10357-10364.
54. Sloan, E.K.; Priceman, S.J.; Cox, B.F.; Yu, S.; Pimentel, M.A.; Tangkanangnukul, V.; Arevalo, J.M.; Morizono, K.; Karanikolas, B.D.; Wu, L.; Sood, A.K. and Cole, S.W. (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res., 70, 7042-7052.
55. Palm, D.; Lang, K.; Niggemann, B.; Drell, T.L.; Masur, K.; Zaenker, K.S. and Entschladen, F. (2006) The norepinephrinedriven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int. J. Cancer, 118, 2744-2749.
56. Algazi, M.; Plu-Bureau, G.; Flahault, A.; Dondon, M.G. and Le, M.G. (2004) [Could treatments with beta-blockers be associated with a reduction in cancer risk?]. Rev. Epidemiol. Sante Publique, 52, 53-65.
57. Holmes, W.J.; Mishra, A.; Gorst, C. and Liew, S.H. (2010) Propranolol as first-line treatment for rapidly proliferating Infantile Haemangiomas. J. Plast. Reconstr. Aesthet. Surg., [Epub ahead of print]
58. Shi, M.; Liu, D.; Duan, H.; Qian, L.; Wang, L.; Niu, L.; Zhang, H.; Yong, Z.; Gong, Z.; Song, L.; Yu, M.; Hu, M.; Xia, Q.; Shen, B. and Guo, N. (2010) The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res. Treat., 125, 351-362.
59. Bucci, B.; D'Agnano, I.; Botti, C.; Mottolese, M.; Carico, E.; Zupi, G. and Vecchione, A. (1997) EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res., 17, 769-774.